Product NDC: | 55513-021 |
Proprietary Name: | ARANESP |
Non Proprietary Name: | darbepoetin alfa |
Active Ingredient(s): | 40 ug/.4mL & nbsp; darbepoetin alfa |
Administration Route(s): | INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 55513-021 |
Labeler Name: | Amgen Inc |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA103951 |
Marketing Category: | BLA |
Start Marketing Date: | 20060814 |
Package NDC: | 55513-021-04 |
Package Description: | 1 BLISTER PACK in 1 PACKAGE (55513-021-04) > 4 SYRINGE in 1 BLISTER PACK > .4 mL in 1 SYRINGE (55513-021-01) |
NDC Code | 55513-021-04 |
Proprietary Name | ARANESP |
Package Description | 1 BLISTER PACK in 1 PACKAGE (55513-021-04) > 4 SYRINGE in 1 BLISTER PACK > .4 mL in 1 SYRINGE (55513-021-01) |
Product NDC | 55513-021 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | darbepoetin alfa |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 20060814 |
Marketing Category Name | BLA |
Labeler Name | Amgen Inc |
Substance Name | DARBEPOETIN ALFA |
Strength Number | 40 |
Strength Unit | ug/.4mL |
Pharmaceutical Classes | Erythropoiesis-stimulating Agent [EPC],Erythropoietin [Chemical/Ingredient],Increased Erythroid Cell Production [PE] |